Neoadjuvant chemotherapy for bladder cancer: current status

Expert Opinion on Pharmacotherapy
Robert Dreicer

Abstract

Muscle-invasive bladder cancer is typically an aggressive solid tumour with the propensity for early systemic dissemination. Although curative-intent local therapy with either radical cystectomy or radiotherapy remains the gold standard intervention, the high rate of systemic failure has prompted investigators to evaluate various strategies in an attempt to improve survival, including the early administration of systemic chemotherapy. Recently completed, Phase III studies of neoadjuvant chemotherapy trials demonstrated a modest, but real survival advantage for a small subset of patients. Other strategies include, attempts to both preserve the bladder using combinations of limited surgical resection, systemic chemotherapy and radiotherapy. This review focuses on the potential of neoadjuvantly-administered therapies to impact the management of muscle invasive bladder cancer.

References

Jul 1, 1982·The Journal of Urology·K W Kaye, P H Lange
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P K SchultzH I Scher
Nov 4, 1993·The New England Journal of Medicine·D S KaufmanJ T Efird
Sep 21, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Sylvester, C Sternberg
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SteinD G Skinner
Mar 8, 2003·Scandinavian Journal of Urology and Nephrology·Amir SherifUNKNOWN Nordic Urothelial Cancer Group

❮ Previous
Next ❯

Citations

Apr 8, 2006·The Journal of Urology·Ganesh S PalapattuUNKNOWN Bladder Cancer Research Consortium

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.